Weiss Ratings Reiterates Sell (D-) Rating for Autolus Therapeutics (NASDAQ:AUTL)

Key Points

• Weiss Ratings has reissued a sell (D-) rating for Autolus Therapeutics (NASDAQ:AUTL), indicating potential concerns about the company's stock performance.
• Analysts have varied opinions on AUTL, with Needham & Company maintaining a buy rating and a target price of $10, while Wells Fargo reduced their target from $6.00 to $5.00.
• Autolus Therapeutics recently reported a quarterly revenue of $13.50 million, exceeding expectations, and a quarterly EPS of ($0.18), beating estimates by $0.06.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report)'s stock had its "sell (d-)" rating reissued by investment analysts at Weiss Ratings in a research note issued to investors on Wednesday,Weiss Ratings reports.

A number of other analysts have also issued reports on AUTL. Needham & Company LLC reaffirmed a "buy" rating and issued a $10.00 price target on shares of Autolus Therapeutics in a research note on Monday, July 21st. Wall Street Zen raised Autolus Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday, August 16th. Wells Fargo & Company reduced their target price on Autolus Therapeutics from $6.00 to $5.00 and set an "overweight" rating on the stock in a research report on Wednesday, August 13th. Finally, William Blair restated an "outperform" rating on shares of Autolus Therapeutics in a report on Wednesday, September 24th. Six investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, Autolus Therapeutics has a consensus rating of "Moderate Buy" and an average target price of $9.12.

Autolus Therapeutics Price Performance

AUTL stock traded up $0.27 during trading on Wednesday, hitting $1.76. 7,652,484 shares of the company traded hands, compared to its average volume of 2,354,983. The stock's 50-day simple moving average is $1.70 and its 200 day simple moving average is $1.78. The company has a market cap of $468.41 million, a PE ratio of -2.10 and a beta of 1.84. Autolus Therapeutics has a 1 year low of $1.11 and a 1 year high of $5.00.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last posted its quarterly earnings data on Tuesday, August 12th. The company reported ($0.18) EPS for the quarter, beating analysts' consensus estimates of ($0.24) by $0.06. The business had revenue of $13.50 million during the quarter, compared to analysts' expectations of $12.92 million. Research analysts expect that Autolus Therapeutics will post -0.94 earnings per share for the current year.

Hedge Funds Weigh In On Autolus Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of AUTL. Marex Group plc acquired a new stake in Autolus Therapeutics in the second quarter worth approximately $28,000. Bank of America Corp DE increased its holdings in shares of Autolus Therapeutics by 2,891.7% in the second quarter. Bank of America Corp DE now owns 975,135 shares of the company's stock valued at $2,223,000 after buying an additional 942,540 shares in the last quarter. Armistice Capital LLC increased its holdings in shares of Autolus Therapeutics by 9.1% in the second quarter. Armistice Capital LLC now owns 12,000,000 shares of the company's stock valued at $27,360,000 after buying an additional 1,000,000 shares in the last quarter. TFG Asset Management GP Ltd increased its holdings in shares of Autolus Therapeutics by 10.5% in the second quarter. TFG Asset Management GP Ltd now owns 9,500,000 shares of the company's stock valued at $21,660,000 after buying an additional 900,000 shares in the last quarter. Finally, The Manufacturers Life Insurance Company increased its holdings in shares of Autolus Therapeutics by 41.6% in the second quarter. The Manufacturers Life Insurance Company now owns 38,419 shares of the company's stock valued at $88,000 after buying an additional 11,289 shares in the last quarter. 72.83% of the stock is currently owned by institutional investors and hedge funds.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.